Recently, novel therapeutic options for NAFLD have been proposed including activation of farnesoid X receptor (FXR) that ameliorates fibrotic and inflammatory damages [11, 12]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.